## **Supplementary Materials**







Figure S1. Western Blot analysis comparing the specificity of antibodies against SNAP25 using SiMa cell lysates treated with (L<sub>3</sub>) or without (L<sub>2</sub>) BoNT/A. (A) Blot probed with a commercially available anti-SNAP25 mAb (SMI-81R) that recognizes both the full-length (206) and cleaved (197) forms of SNAP25. In lane 2, only SNAP25<sub>206</sub> is detected, whereas in lane 3, both SNAP25206 (arrow) and SNAP25197 (arrowhead) are detected; (B) Blot probed with a commercially available anti-SNAP25 mAb (MC-6050) that reportedly recognizes both SNAP25206 and SNAP25197. Only SNAP25197 appears as a single band in lane 3 (arrowhead); (C) Blot probed with a commercially available anti-SNAP25 mAb (MC-6053) that is reportedly specific for SNAP25197. The antibody does not appear to recognize any bands; (**D**) Blot probed with Ab632 anti-SNAP25<sub>197</sub> rMAb. In lane 2, no band is detected, whereas in lane 3, a single band for SNAP25<sub>197</sub> is detected (arrowhead); (E) Blot probed with Ab635 anti-SNAP25<sub>197</sub> rMAb. In lane 2, no band is detected, whereas in lane 3, a single band for SNAP25<sub>197</sub> is detected (arrowhead); (F) Blot probed with RGT-1092 anti-SNAP25<sub>197</sub> pAb. This antibody primarily recognizes SNAP25<sub>197</sub> in lane 3 (arrowhead), although two faint bands are visible just above and below the SNAP25197 band. Lane 1, protein ladder; Lane 2, untreated SiMa cell lysate; Lane 3, BoNT/A-treated (0.01 nM) SiMa cell lysate.



**Figure S2.** Control blots for the cortical cell studies in Figure 1 (**A**) and SiMa cell studies in Figure S1 (**B**) probed with anti-GAPDH mAb showing equal loading of samples in lanes 2 and 3. Lane 1, protein ladder; Lane 2, untreated cell lysate; Lane 3, BoNT/A-treated (3 nM) cortical cell lysate or (0.01 nM) SiMa cell lysate; (**C**,**D**) Western Blot analysis showing the epitope specificity of Ab632-rMAb using SiMa cell lysates treated with BoNT/A (L<sub>3</sub>), BoNT/C (L<sub>4</sub>), BoNT/E (L<sub>5</sub>) or with no toxin (L<sub>2</sub>). (**C**) Blot probed with a commercially available anti-SNAP25 mAb (SMI-81R) that recognizes both the full-length (206) and cleaved (197 for BoNT/A, 198 for BoNT/C and 180 for BoNT/E) forms of SNAP25. In lane 2, only SNAP25<sub>206</sub> is detected, whereas in lane 3, both SNAP25<sub>206</sub> (arrow) and SNAP25<sub>197</sub> are detected. In lane 4, both SNAP25<sub>206</sub> (arrow) and SNAP25<sub>198</sub> are detected and in lane 5, both SNAP25<sub>206</sub> (arrow) and SNAP25<sub>180</sub> are detected; (**D**) Blot probed with Ab632 anti-SNAP25<sub>197</sub> rMAb. In lane 2, 4 and 5, no band is detected, whereas in lane 3, a single band for SNAP25<sub>197</sub> is detected. Lane 1, protein ladder; Lane 2, untreated SiMa cell lysate; Lane 3, BoNT/A-treated SiMa cell lysate; Lane 4, BoNT/C-treated SiMa cell lysate; Lane 5, BoNT/E-treated SiMa cell lysate.



**Figure S3.** Immunohistochemical analysis showing the specificity of Ab635-rMAb in sections of rat bladder and glabrous skin following treatment with either onabotulinumtoxinA (10 U/kg, bladder; 30 U/kg, skin) or vehicle. (**A,B**) Confocal images of rat bladder detrusor muscle (**A**) and blood vessels within rat glabrous skin (**B**) showing IR-signal (arrows, green) in the nerve fibers following onabotulinumtoxinA treatment; (**C,D**) Confocal images of control rat bladder and skin injected with vehicle; (**E,F**) Confocal images of adjacent sections of rat bladder (**E**) and glabrous skin (**F**) processed without primary antibodies showing only background staining. DM, detrusor muscle; BV, blood vessels; Scale bar = 50  $\mu$ m.



**Figure S4.** Immunohistochemical analysis comparing the specificity of antibodies against SNAP25 in skeletal muscle underlying rat glabrous skin following treatment with either onabotulinumtoxinA (30 U/kg) or vehicle. (**A–D**) Confocal images showing motor nerve terminals (MNT, arrows) within the underlying muscle of the rat paw injected with onabotulinumtoxinA and probed with (**A**) commercial mAb (SMI-81R) against full-length (206) and cleaved (197) SNAP25; (**B**) a second commercial mAb (MC-6050) against SNAP25<sub>197</sub> & SNAP25<sub>206</sub>; (**C**) a commercial mAb (MC-6053) against SNAP25<sub>197</sub> and (**D**) Ab632-rMAb against SNAP25<sub>197</sub>; (**E–H**) Confocal images from control rat paw injected with vehicle and probed with the same four antibodies. SNAP25-IR signal is in green and DIC illumination was used to delineate the underlying muscle fibers (MF). Arrow (**E**) points to IR-signal within a MNT from vehicle treated rat paw; asterisks (**B,C,F** and **G**) point to non-specific IR-signal within the muscle. Scale bar = 50 μm.